At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
TD-9855 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
In Brief
A Phase 2 clinical trial evaluating TD-9855 and Placebo for Neurogenic Orthostatic Hypotension and 7 related conditions. Completed, enrolled 34 participants across 6 sites.
Detailed Summary
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic orthostatic hypotension to evaluate the effect of TD-9855 in improving symptoms of orthostatic intolerance.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartSep 2017
Primary CompletionJul 2018
Study CompletionNov 2018
TodayJul 2026
First PostedMar 10, 2016
Enrollment StartSep 9, 2017
Primary CompletionJul 24, 2018
Study CompletionNov 28, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.3 years ago
Interventions
TD-9855drug
Administered orally.
Placebodrug
Administered orally.